Unknown

Dataset Information

0

15 N NMR Hyperpolarization of Radiosensitizing Antibiotic Nimorazole by Reversible Parahydrogen Exchange in Microtesla Magnetic Fields.


ABSTRACT: Nimorazole belongs to the imidazole-based family of antibiotics to fight against anaerobic bacteria. Moreover, nimorazole is now in Phase 3 clinical trial in Europe for potential use as a hypoxia radiosensitizer for treatment of head and neck cancers. We envision the use of [15 N3 ]nimorazole as a theragnostic hypoxia contrast agent that can be potentially deployed in the next-generation MRI-LINAC systems. Herein, we report the first steps to create long-lasting (for tens of minutes) hyperpolarized state on three 15 N sites of [15 N3 ]nimorazole with T1 of up to ca. 6 minutes. The nuclear spin polarization was boosted by ca. 67000-fold at 1.4 T (corresponding to P15N of 3.2 %) by 15 N-15 N spin-relayed SABRE-SHEATH hyperpolarization technique, relying on simultaneous exchange of [15 N3 ]nimorazole and parahydrogen on polarization transfer Ir-IMes catalyst. The presented results pave the way to efficient spin-relayed SABRE-SHEATH hyperpolarization of a wide range of imidazole-based antibiotics and chemotherapeutics.

SUBMITTER: Salnikov OG 

PROVIDER: S-EPMC7855180 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

<sup>15</sup> N NMR Hyperpolarization of Radiosensitizing Antibiotic Nimorazole by Reversible Parahydrogen Exchange in Microtesla Magnetic Fields.

Salnikov Oleg G OG   Chukanov Nikita V NV   Svyatova Alexandra A   Trofimov Ivan A IA   Kabir Mohammad S H MSH   Gelovani Juri G JG   Kovtunov Kirill V KV   Koptyug Igor V IV   Chekmenev Eduard Y EY  

Angewandte Chemie (International ed. in English) 20201201 5


Nimorazole belongs to the imidazole-based family of antibiotics to fight against anaerobic bacteria. Moreover, nimorazole is now in Phase 3 clinical trial in Europe for potential use as a hypoxia radiosensitizer for treatment of head and neck cancers. We envision the use of [<sup>15</sup> N<sub>3</sub> ]nimorazole as a theragnostic hypoxia contrast agent that can be potentially deployed in the next-generation MRI-LINAC systems. Herein, we report the first steps to create long-lasting (for tens o  ...[more]

Similar Datasets

| S-EPMC8172086 | biostudies-literature
| S-EPMC5580346 | biostudies-literature
| S-EPMC5578426 | biostudies-literature
| S-EPMC5378067 | biostudies-literature
| S-EPMC10642564 | biostudies-literature
| S-EPMC4419867 | biostudies-literature
| S-EPMC8361944 | biostudies-literature
| S-EPMC11884822 | biostudies-literature
| S-EPMC10427394 | biostudies-literature
| S-EPMC5561492 | biostudies-literature